

# Sarah E Ferguson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3412194/publications.pdf>

Version: 2024-02-01

72  
papers

1,872  
citations

361413

20  
h-index

289244

40  
g-index

73  
all docs

73  
docs citations

73  
times ranked

3578  
citing authors

#	ARTICLE	IF	CITATIONS
1	Ovarian cancer incidence and death in average-risk women undergoing bilateral salpingo-oophorectomy at benign hysterectomy. <i>American Journal of Obstetrics and Gynecology</i> , 2022, 226, 220.e1-220.e26.	1.3	8
2	Impact of care by gynecologic oncologists on primary ovarian cancer survival: A population-based study. <i>Gynecologic Oncology</i> , 2022, 164, 522-528.	1.4	3
3	Pre-operative wait times in high-grade non-endometrioid endometrial cancer: Do surgical delays impact patient survival?. <i>Gynecologic Oncology</i> , 2022, 164, 333-340.	1.4	4
4	Sentinel Lymph Node Mapping in High-Grade Endometrial Cancer. <i>Current Oncology</i> , 2022, 29, 1123-1135.	2.2	6
5	Sentinel lymph node biopsy in high-grade endometrial cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2022, , .	1.3	0
6	A prospective comparison of costs between robotics, laparoscopy, and laparotomy in endometrial cancer among women with Class III obesity or higher. <i>Journal of Surgical Oncology</i> , 2022, 125, 747-753.	1.7	3
7	External Validation of O-RADS US Risk Stratification and Management System. <i>Radiology</i> , 2022, 304, 114-120.	7.3	28
8	Implementation of a standardized voiding protocol after minimally invasive surgery: A quality improvement initiative. <i>International Journal of Gynecology and Obstetrics</i> , 2022, 159, 696-701.	2.3	1
9	The added value of SLN mapping with indocyanine green in low- and intermediate-risk endometrial cancer management: a systematic review and meta-analysis. <i>Journal of Gynecologic Oncology</i> , 2022, 33, .	2.2	11
10	Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 217-228.	2.5	12
11	Assessment of Sentinel Lymph Node Biopsy vs Lymphadenectomy for Intermediate- and High-Grade Endometrial Cancer Staging. <i>JAMA Surgery</i> , 2021, 156, 157.	4.3	118
12	An Integrative DNA Sequencing and Methylation Panel to Assess Mismatch Repair Deficiency. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 242-252.	2.8	12
13	Evaluating the effect of a group pre-treatment chemotherapy psycho-education session for chemotherapy-naive gynecologic cancer patients and their caregivers. <i>Gynecologic Oncology</i> , 2021, 160, 234-243.	1.4	2
14	An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline: Consolidation or Maintenance Systemic Therapy for Newly Diagnosed Stage II, III, or IV Epithelial Ovary, Fallopian Tube, or Primary Peritoneal Carcinoma. <i>Current Oncology</i> , 2021, 28, 1114-1124.	2.2	4
15	Understanding the clinical implication of mismatch repair deficiency in endometrioid endometrial cancer through a prospective study. <i>Gynecologic Oncology</i> , 2021, 161, 221-227.	1.4	9
16	Performance characteristics of brief family history questionnaire to screen for Lynch syndrome in women with newly diagnosed ovarian cancers.. <i>Journal of Clinical Oncology</i> , 2021, 39, e22525-e22525.	1.6	0
17	Sentinel Lymph Node Concept in High-Risk Profile Endometrial Cancer—Reply. <i>JAMA Surgery</i> , 2021, 156, 799-800.	4.3	0
18	Sentinel lymph node biopsy in high-grade endometrial cancer: a systematic review and meta-analysis of performance characteristics. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 225, 367.e1-367.e39.	1.3	39

#	ARTICLE	IF	CITATIONS
19	Maximizing cancer prevention through genetic navigation for Lynch syndrome detection in women with newly diagnosed endometrial and nonserous/nonmucinous epithelial ovarian cancer. <i>Cancer</i> , 2021, 127, 3082-3091.	4.1	6
20	Practice variation in bilateral salpingo-oophorectomy at benign abdominal hysterectomy: a population-based study. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 224, 585.e1-585.e30.	1.3	9
21	Consolidation or maintenance systemic therapy for newly diagnosed stage II, III, or IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 162, 103336.	4.4	3
22	The Prevent Ovarian Cancer Program (POCP): Identification of women at risk for ovarian cancer using complementary recruitment approaches. <i>Gynecologic Oncology</i> , 2021, 162, 97-106.	1.4	3
23	Gynecologic oncology treatment modifications or delays in response to the COVID-19 pandemic in a publicly funded versus privately funded North American tertiary cancer center. <i>Gynecologic Oncology</i> , 2021, 162, 12-17.	1.4	7
24	Efficacy and toxicity of intraperitoneal chemotherapy as compared to intravenous chemotherapy in the treatment of patients with advanced ovarian cancer. <i>International Journal of Gynecology and Obstetrics</i> , 2021, , .	2.3	3
25	Endometrial cancer. <i>Cmaj</i> , 2021, 193, E1423-E1423.	2.0	9
26	Treatment outcomes and predictive factors in patients ≥70 years old with advanced ovarian cancer. <i>Journal of Surgical Oncology</i> , 2021, , .	1.7	3
27	Association of bilateral salpingo-oophorectomy with all cause and cause specific mortality: population based cohort study. <i>BMJ, The</i> , 2021, 375, e067528.	6.0	22
28	Reply. <i>American Journal of Obstetrics and Gynecology</i> , 2020, 222, 96-97.	1.3	2
29	Year 1: Experiences of a tertiary cancer centre following implementation of reflex BRCA1 and BRCA2 tumor testing for all high-grade serous ovarian cancers in a universal healthcare system. <i>Gynecologic Oncology</i> , 2020, 158, 747-753.	1.4	12
30	Management of gynecologic cancer: Choosing radiotherapy wisely by 3 Southern Ontario academic centers during the COVID-19 pandemic. <i>Radiotherapy and Oncology</i> , 2020, 151, 15-16.	0.6	6
31	Class III Obesity and Other Factors Associated with Longer Wait Times for Endometrial Cancer Surgery: A Population-Based Study. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2020, 42, 1093-1102.e3.	0.7	3
32	Performance characteristics of screening strategies to identify Lynch syndrome in women with ovarian cancer. <i>Cancer</i> , 2020, 126, 4886-4894.	4.1	15
33	Oncologic outcomes and morbidity following heated intraperitoneal chemotherapy at cytoreductive surgery for primary epithelial ovarian cancer: A systematic review and meta-analysis. <i>Gynecologic Oncology</i> , 2020, 158, 218-228.	1.4	12
34	Supported self-management as a model for end-of-life care in the setting of malignant bowel obstruction: A qualitative study. <i>Gynecologic Oncology</i> , 2020, 157, 745-753.	1.4	9
35	The use of indocyanine green fluorescence angiography to assess anastomotic perfusion following bowel resection in surgery for gynecologic malignancies - A report of 100 consecutive anastomoses. <i>Gynecologic Oncology</i> , 2020, 158, 402-406.	1.4	10
36	Long-term survival outcomes of intravenous versus intraperitoneal chemotherapy in the treatment of advanced ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 6046-6046.	1.6	1

#	ARTICLE	IF	CITATIONS
37	Risk stratified multidisciplinary ambulatory management of malignant bowel obstruction (MAMBO) program for women with gynecological cancers: Preliminary results from a prospective single-center study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 6062-6062.	1.6	1
38	Impact of surgical approach on oncologic outcomes in women undergoing radical hysterectomy for cervical cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2019, 221, 619.e1-619.e24.	1.3	102
39	Barriers to care for women with low-grade endometrial cancer and morbid obesity: a qualitative study. <i>BMJ Open</i> , 2019, 9, e026872.	1.9	16
40	Laparoscopic and robotic hysterectomy in endometrial cancer patients with obesity: a systematic review and meta-analysis of conversions and complications. <i>American Journal of Obstetrics and Gynecology</i> , 2019, 221, 410-428.e19.	1.3	87
41	Optimizing the Care of Malignant Bowel Obstruction in Patients With Advanced Gynecologic Cancer. <i>Journal of Oncology Practice</i> , 2019, 15, e1066-e1075.	2.5	16
42	Interobserver Agreement for Mismatch Repair Protein Immunohistochemistry in Endometrial and Nonserous, Nonmucinous Ovarian Carcinomas. <i>American Journal of Surgical Pathology</i> , 2019, 43, 591-600.	3.7	21
43	Prospective cohort study comparing quality of life and sexual health outcomes between women undergoing robotic, laparoscopic and open surgery for endometrial cancer. <i>Gynecologic Oncology</i> , 2018, 149, 476-483.	1.4	50
44	The prognostic value of perioperative, pre-systemic therapy <sc>CA</sc> 125 levels in patients with high-grade serous ovarian cancer. <i>International Journal of Gynecology and Obstetrics</i> , 2018, 140, 247-252.	2.3	18
45	Towards the validation of a new, blended theoretical model of fear of cancer recurrence. <i>Psycho-Oncology</i> , 2018, 27, 2594-2601.	2.3	49
46	Malignant Bowel Obstruction in Advanced Gynecologic Cancers: An Updated Review from a Multidisciplinary Perspective. <i>Obstetrics and Gynecology International</i> , 2018, 2018, 1-10.	1.3	23
47	Empowering patients and caregivers with knowledge: The development of a nurse-led gynecologic oncology chemotherapy education class. <i>Canadian Oncology Nursing Journal = Revue Canadienne De Nursing Oncologique</i> , 2018, 28, 4-7.	0.5	9
48	Brachy-ing Unresectable Endometrial Cancers with Magnetic Resonance Guidance. <i>Cureus</i> , 2018, 10, e2274.	0.5	4
49	Accessing care: Experiences and perceptions of morbidly obese women diagnosed with low-grade endometrial cancer—A qualitative study.. <i>Journal of Clinical Oncology</i> , 2018, 36, e18658-e18658.	1.6	0
50	Comparison of three surgical approaches for staging lymphadenectomy in high-risk endometrial cancer. <i>International Journal of Gynecology and Obstetrics</i> , 2017, 136, 315-319.	2.3	13
51	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature Genetics</i> , 2017, 49, 680-691.	21.4	356
52	Implementing a Cervical Sentinel Lymph Node Biopsy Program: Quality Improvement in Gynaecologic Oncology. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2017, 39, 659-667.	0.7	10
53	Is adjuvant chemotherapy beneficial for surgical stage I ovarian clear cell carcinoma?. <i>Gynecologic Oncology</i> , 2017, 147, 54-60.	1.4	12
54	Progesterone receptor expression is associated with longer overall survival within high-grade histotypes of endometrial carcinoma: A Canadian high risk endometrial cancer consortium (CHREC) study. <i>Gynecologic Oncology</i> , 2016, 141, 559-563.	1.4	25

#	ARTICLE	IF	CITATIONS
55	Protocol of a randomized controlled trial of the fear of recurrence therapy (FORT) intervention for women with breast or gynecological cancer. <i>BMC Cancer</i> , 2016, 16, 291.	2.6	45
56	Treatment related outcomes in high-risk endometrial carcinoma: Canadian high risk endometrial cancer consortium (CHREC). <i>Gynecologic Oncology</i> , 2016, 141, 148-154.	1.4	34
57	A comparison of the toxicity and tolerability of two intraperitoneal chemotherapy regimens for advanced-stage epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2016, 140, 36-41.	1.4	17
58	The optimal time for surgery in women with serous ovarian cancer. <i>Canadian Journal of Surgery</i> , 2016, 59, 223-232.	1.2	16
59	Ovarian cancer pathway map development as an approach to identifying priority areas for quality improvement in Ontario.. <i>Journal of Clinical Oncology</i> , 2016, 34, e18190-e18190.	1.6	0
60	Performance characteristics of a brief Family History Questionnaire to screen for Lynch syndrome in women with newly diagnosed endometrial cancer. <i>Gynecologic Oncology</i> , 2015, 136, 311-316.	1.4	9
61	Canadian high risk endometrial cancer (CHREC) consortium: Analyzing the clinical behavior of high risk endometrial cancers. <i>Gynecologic Oncology</i> , 2015, 139, 268-274.	1.4	50
62	An analysis of malignant bowel obstruction (MBO) outcomes in patients with epithelial ovarian carcinoma (EOC).. <i>Journal of Clinical Oncology</i> , 2015, 33, e16586-e16586.	1.6	1
63	Performance characteristics of screening strategies for Lynch syndrome in unselected women with newly diagnosed endometrial cancer who have undergone universal germline mutation testing. <i>Cancer</i> , 2014, 120, 3932-3939.	4.1	114
64	The Fallopian Tube as the Origin of High Grade Serous Ovarian Cancer: Review of a Paradigm Shift. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2014, 36, 133-140.	0.7	70
65	Fertility sparing treatment of complex atypical hyperplasia and low grade endometrial cancer using oral progestin. <i>Gynecologic Oncology</i> , 2014, 133, 229-233.	1.4	73
66	Risk-Reducing Salpingectomy in Canada: A Survey of Obstetrician-Gynaecologists. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2013, 35, 627-634.	0.7	34
67	Screening for Lynch syndrome in unselected women with endometrial cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 5508-5508.	1.6	0
68	Confirmatory factor analysis of the Sexual Adjustment and Body Image Scale in women with gynecologic cancer. <i>Cancer</i> , 2012, 118, 3095-3104.	4.1	13
69	Comparison of clinical schemas and morphologic features in predicting Lynch syndrome in mutationâ€positive patients with endometrial cancer encountered in the context of familial gastrointestinal cancer registries. <i>Cancer</i> , 2012, 118, 681-688.	4.1	71
70	A prospective randomized trial comparing patient-controlled epidural analgesia to patient-controlled intravenous analgesia on postoperative pain control and recovery after major open gynecologic cancer surgery. <i>Gynecologic Oncology</i> , 2009, 114, 111-116.	1.4	52
71	Heparin for pregnant women with acquired or inherited thrombophilias. <i>The Cochrane Library</i> , 2003, , CD003580.	2.8	26
72	Preterm premature rupture of membranes Nutritional and socioeconomic factors. <i>Obstetrics and Gynecology</i> , 2002, 100, 1250-1256.	2.4	40